Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site
- PMID: 10484767
- DOI: 10.1093/hmg/8.11.1989
Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site
Abstract
The RET gene codes for a transmembrane tyrosine kinase which is a subunit of a multimeric complex that acts as a receptor for four structurally related molecules: the glial cell line-derived neurotrophic factor (GDNF), neurturin, artemin and persephin. Germline mutations of RET cause a dominantly inherited dysgenesis of the enteric nervous system known as Hirschsprung's disease (HSCR; aganglionosis megacolon). The majority of HSCR mutations results either in a reduction of dosage of the RET protein or in the loss of RET function. Two novel distinct mutations of RET that led either to the deletion of codon 1059 (denoted Delta1059) or to the substitution of a Pro for Leu1061 have been identified in five HSCR families. In one large pedigree, two children born from asymptomatic consanguineous parents presented a severe form of HSCR and were found to carry the mutation at codon 1061 in the homozygous state. A tyrosine residue at position 1062 is an intracytoplasmic docking site that enables RET to recruit several signalling molecules, including the Shc adaptor protein. We now report that both HSCR mutations impair the fixation of Shc to RET and consequently prevent its phosphorylation. In addition, quantitative analysis in PC12 cells reveals that mutation Delta1059 inactivates the ability of RET to transduce a downstream signal whereas mutation L1061P only partially inhibits the signalling of RET. Finally, we provide evidence that these effects are partly mediated via the disruption of the RET/Shc interaction. Collectively, these results demonstrate that HSCR can be ascribed to mutations of RET which interfere with the binding of transduction effectors, such as Shc, and further provide a biochemical explanation for the phenotype of patients carrying a homozygous mutation at codon 1061. Finally, these data indicate that Y1062 is a multifunctional docking site that confers to RET the capacity to engage downstream signalling pathways which exert a crucial role during enteric neurogenesis.
Similar articles
-
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.Endocrinology. 1998 Aug;139(8):3613-9. doi: 10.1210/endo.139.8.6124. Endocrinology. 1998. PMID: 9681515
-
Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.J Clin Invest. 1998 Mar 15;101(6):1415-23. doi: 10.1172/JCI375. J Clin Invest. 1998. PMID: 9502784 Free PMC article.
-
Grb2 binding to the different isoforms of Ret tyrosine kinase.Oncogene. 1998 Sep 3;17(9):1079-87. doi: 10.1038/sj.onc.1202046. Oncogene. 1998. PMID: 9764818
-
[From monogenic to polygenic: model of Hirschsprung disease].Pathol Biol (Paris). 1998 Nov;46(9):705-7. Pathol Biol (Paris). 1998. PMID: 9885824 Review. French.
-
Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.Recent Results Cancer Res. 1998;154:229-36. doi: 10.1007/978-3-642-46870-4_14. Recent Results Cancer Res. 1998. PMID: 10027003 Review.
Cited by
-
Sequence characterization of RET in 117 Chinese Hirschsprung disease families identifies a large burden of de novo and parental mosaic mutations.Orphanet J Rare Dis. 2019 Oct 30;14(1):237. doi: 10.1186/s13023-019-1194-2. Orphanet J Rare Dis. 2019. PMID: 31666091 Free PMC article.
-
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.Mol Cell Biol. 2001 Jul;21(13):4177-87. doi: 10.1128/MCB.21.13.4177-4187.2001. Mol Cell Biol. 2001. PMID: 11390647 Free PMC article.
-
Low RET mutation frequency and polymorphism analysis of the RET and EDNRB genes in patients with Hirschsprung disease in Taiwan.J Hum Genet. 2005;50(4):168-174. doi: 10.1007/s10038-005-0236-x. Epub 2005 Apr 15. J Hum Genet. 2005. PMID: 15834508
-
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):307-318. doi: 10.1016/j.beem.2017.04.013. Epub 2017 May 10. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911727 Free PMC article. Review.
-
RET receptor signaling: Function in development, metabolic disease, and cancer.Proc Jpn Acad Ser B Phys Biol Sci. 2022;98(3):112-125. doi: 10.2183/pjab.98.008. Proc Jpn Acad Ser B Phys Biol Sci. 2022. PMID: 35283407 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous